A firm based in Western Europe focuses on investing in digital health, devices and diagnostics technologies. Though an early investor, the firm looks for companies that have some proof of concept data. The firm will consider investments in North America and Europe. The firm generally looks to invest between 100K-2M EUR in their portfolio companies.
The firm will invest in digital health as well as diagnostics and devices as well as regenerative medicine technologies. For diagnostics and devices, the firm prefers companies with a digital component. In addition, the firm prefers devices without complex regulatory requirements. The firm is agnostic with regards to indication.
The firm is willing to lead or co-invest. Generally, the firm prefers to have a board or an observer seat after investing. Within the life sciences, the firm prefers to invest in teams with industry experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm Invests in Devices, Diagnostics, and Digital Health Companies in North America and Europe, Preferring Technologies With Digital Component
30 JunRESI Boston Pitch Applications Now Open
23 JunBy Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
One of the best parts of RESI returning to an in-person format after more than two years is the return of the live pitch session! RESI Boston returns in-person September 21-22, with an additional day of dedicated-digital partnering September 23. Applications to pitch for the Innovator’s Pitch Challenge (IPC) are now open until Friday, August 12! The IPC was created to respond to the need for a digital pitch format. Now it has been modified to bring the value and function to an in-person format.
What Is It?
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts. Participating companies pay to host their company materials on the Live Agenda and participate in the live pitch session.
How Does It Work?
Pitching companies will have a dedicated webpage on the RESI Live Agenda, which greatly increases visibility to investors and other registered attendees. Companies can share their marketing collateral such as their slide deck, executive summary, optional pitch video, and more.
Each pitching company will be assigned to an IPC session, with each session featuring four companies, grouped together based on similar sector and/or technology. Companies will be given four minutes to pitch, followed by an additional ten minutes of Q&A and feedback from the judging panel.
Who Should Apply?
Early-stage life science companies actively raising seed capital ($25K – 2M), Series A ($2 – 10M), or Series B ($10 – 50M) use the IPC to get in front of the panel of qualified investor judges in their market segment and pitch their company and product. Early-stage companies are encouraged to apply and submit their pitch deck and executive summary.
Branding Opportunities at RESI Boston
23 JunBy Candice He, Vice President of Business Development, Global Investment Strategist, LSN
RESI returns to an in-person format after more than two years this September, and now is the time to start planning exhibit and sponsorship engagements to hundreds of RESI attendees at the hub of life science industry – Boston, MA. Whether service providers increasing deal pipeline, big pharma sourcing technology assets, or just looking to connect with early-stage startups at pre-clinical/phase I stage, RESI Boston is the place to get started! With 350+ life science investors and big pharma, 200+ early-stage company executives, and dozens of delegations from global incubators, universities, and organizations, there’s no better place to connect with ideal partners and start those meaningful conversations.
To showcase products and services, RESI offers a range of sponsorship opportunities, including dedicated workshops, exhibition tables, and newsletter interviews. Prominent logo displays throughout both the digital platform and onsite signage will greatly increase brand visibility, as well as program guide ads, onsite meal or material sponsorship, session signage, pitch judging, and more.
Check out sponsorship opportunities for RESI Boston, September 21-23. For more information about sponsorship, advertising, and exhibit opportunities, contact our dedicated BD team. We look forward to helping you meet your goals!
Tech Hub Exposure at RESI Boston
23 JunBy Erika Wu, Business Development Manager, Global Tech Hubs, LSN
RESI Boston returns to an in-person format this September, and if you’re part of a tech hub, RESI is the place to be! Join RESI’s global tech hub ecosystem of accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations who set up their early-stage life science startup constituents for success with their entrepreneurship journey. Recently, RESI has hosted tech hubs ranging from National Institute of Aging (NIA), The Massachusetts Medical Device Development Center (M2D2), Government of Ontario, Yale Ventures, and more.
Through RESI partnership, tech hub startup constituents gain access to resources beyond partnering with investors and strategic partners, such as the Life Science Nation (LSN)’s Investor Database, Innovator’s Pitch Challenge (IPC), free workshops, and Entrepreneurial Immersion Courses, to help develop compelling marketing materials, build meaningful relationships with investors and secure necessary early-stage funding.
At RESI Boston, tech hub organizations and their startup constituents who’ve raised less than $2M can utilize:
- 50% discount for startup constituent registration (startup must be from LSN’s tech hub partners)
- Complimentary tech hub staff registration
- Group Fundraising Investor Database Package (3 startups minimum): 4-month access to the Investor Database
- Dedicated onsite-only Innovator’s Pitch Challenge (IPC) session
- Exhibition space
If you’re a member of a tech hub or looking to add value to your members, reach out to see which offerings best fit your needs. From lab to clinic, and providers to patients, LSN is accelerating the growth and success of companies emerging from tech hubs.
For more information about tech hub offer, please contact Erika Wu, Business Development Manager, Global Tech Hubs at e.wu@lifesciencenation.com.
Hot Investor Mandate: Corporate VC Firm Invests Up to $10M in Therapeutics and Digital Health in Areas that Strategically Align with Parent Company’s Interest Areas
23 JunA corporate venture capital firm with offices in USA and Western Europe invests from an evergreen fund. The firm interested in life science opportunities globally, and expects to make 3-4 new investments per year. The firm typically invests about $10 million over the life of an investment. The fund is typically a lead investor, and participates in syndicates with other investment firms. The firm does not attach rights or options to equity investments; the fund’s allocations are ‘no strings attached’. The firm considers opportunities globally but focuses on Europe, Middle East and North America.
The firm is strategically mandated to invest in opportunities beyond the corporate’s core areas of business. The fund seeks to invest in companies with therapeutic platform technologies and digital health. The firm is only interested in novel technologies; while the fund will consider investing in any form of therapeutic technology, regenerative medicine, cell therapies and gene therapies are the areas of greatest interest. The fund is focused on investing in oncology (particularly immuno-oncology), but will also consider opportunities in other indication areas that lie outside of the corporate’s present core therapeutic fields. Areas in which the parent company has strength, such as respiratory disorders and diabetes, will generally not receive investment from the firm. The firm generally invests in preclinical assets.
The firm invests in technologies of strategic importance to the parent company. The firm only invests in privately held companies. The firm typically does not invest in single asset opportunities; only companies with multiple pipeline assets are of interest. The firm is often the first outside investor in a company, and prefers to invest in opportunities where the firm’s allocation can secure a meaningful stake in the company (a board seat is a requirement).
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Investment Arm of Biotech Company Invests in Seed to Series A Rounds, With Strong Focus on Novel, Pre-Clinical Small Molecule Therapeutics
23 JunThe investment division of a biotech company is solely dedicated to the identification and success of early-stage, biotech start-ups for the firm’s incubation and investment platforms. The firm’s commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.
The firm invests globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. Leveraging the firm’s experience and technical advantages in the field of novel drug R&D, the firm provides both cash and in-kind services (EFS) for their investment. Additionally, based on the need, the firm also offers value-added services in operation and logistic support, BD and Financing assistance, etc. to accelerate the growth of its portfolio companies. The firm can allocate from $500,000 to $5,000,000 of equity capital or convertible notes in seed or Series A.
The firm focuses on novel, preclinical therapeutics and is agnostic to indication, modality and geography. The firm is currently most interested in small molecule first-in-class drugs but is open to considering all drug types. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Diagnostics, Medical Devices, or Healthcare IT companies.
The firm does not have specific requirements for companies or management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm With USA & Europe Offices Invests in Venture to Growth-Stage Digital Health Companies and Data-Driven Devices & Diagnostics Companies
23 JunA venture capital firm with offices in USA and Europe is actively seeking innovative investment opportunities with high potential for growth. With their latest fund, the firm invests in digital technologies in the life sciences space. The firm prefers to invest in venture to growth stage companies – in general, companies looking for seed funding will be considered too early-stage for the firm. With this fund, the firm seeks to make 18-20 investments with initial investment sizes in the range of $3-10M. The firm will focus on companies that are based in USA, Canada, and Western Europe, but may review those from other geographies on a case by case basis.
The firm is most interested in life science companies with a digital component. This includes healthcare IT/digital health, utilization of AI/machine learning for drug discovery, genomics, precision medicine, etc. The firm is open to medical devices or diagnostics that have a digital component. In particular, the firm is most interested in technologies that are dedicated to the treatment of chronic disorders and lead to improved outcomes and lower care costs in hospital systems. The firm will not consider traditional biopharmaceutical modalities.
The firm carefully evaluates investment opportunities based on the quality and experienced of the management team as well as market opportunity. The firm is open to both leading and co-investing, and in the former case will seek board representation.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 